The lichen planus market size has grown strongly in recent years. It will grow from $1.26 billion in 2025 to $1.35 billion in 2026 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to increased diagnosis of autoimmune skin disorders, availability of corticosteroid therapies, expansion of dermatology specialty clinics, improved clinical awareness of lichen planus, use of phototherapy techniques.
The lichen planus market size is expected to see strong growth in the next few years. It will grow to $1.76 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to growing demand for advanced immunotherapies, rising focus on long-term symptom control, expansion of biologic treatment research, increasing integration of digital dermatology tools, advancements in targeted anti-inflammatory drugs. Major trends in the forecast period include increasing adoption of targeted immunomodulatory therapies, rising use of topical and systemic treatment combinations, increasing focus on chronic disease management, expansion of personalized dermatology care, improved patient education and disease monitoring.
The rising prevalence of autoimmune diseases is expected to drive the growth of the lichen planus market in the coming years. Autoimmune diseases are conditions in which the immune system mistakenly attacks the body’s own healthy cells and include disorders such as rheumatoid arthritis, lupus, type 1 diabetes, multiple sclerosis, and psoriasis. The increasing occurrence of autoimmune diseases is largely attributed to genetic predisposition, as certain gene variations influence immune system behavior and connective tissue abnormalities. This growing burden of autoimmune conditions reflects broader immune system dysregulation and contributes to a higher incidence of lichen planus. For example, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, approximately 514,000 people, or 2% of the population, were living with rheumatoid arthritis in 2022. This condition accounted for 2% of the total disease burden and 16% of the musculoskeletal disease burden in 2023, with 1,322 deaths recorded in 2022, representing 0.7% of all deaths. Therefore, the increasing prevalence of autoimmune diseases is contributing to the expansion of the lichen planus market.
Major companies operating in the lichen planus market are focusing on the development of innovative treatment approaches, such as liposomal formulations, to improve targeted drug delivery and reduce systemic side effects. Liposomal formulations are advanced drug delivery systems in which active pharmaceutical ingredients are encapsulated within lipid-based vesicles, enhancing drug stability, absorption, and targeted delivery while minimizing unwanted systemic exposure. For instance, in February 2025, Lipella Pharmaceuticals Inc., a US-based biotechnology company specializing in treatments for serious diseases, received approval from the US Food and Drug Administration for an expanded access program for LP-310. This therapy is a liposomal formulation of tacrolimus designed to provide targeted symptom relief for patients with oral lichen planus while limiting systemic absorption. The expanded access program allows patients with serious or life-threatening conditions and unmet medical needs to access the treatment outside of clinical trials prior to formal regulatory approval.
In September 2024, Eli Lilly and Company, a US-based pharmaceutical firm, partnered with EVA Pharma to expand access to baricitinib (Olumiant) across 49 low- and middle-income countries in Africa. The collaboration aims to reach approximately 20,000 patients by 2030, addressing conditions including lichen planus, rheumatoid arthritis, alopecia areata, and atopic dermatitis. Under the agreement, Eli Lilly will share specific manufacturing expertise to enable EVA Pharma to locally manufacture and distribute the medication. EVA Pharma is an Egypt-based pharmaceutical company engaged in the production and commercialization of generic prescription medicines across multiple therapeutic areas.
Major companies operating in the lichen planus market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc, AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Dr. Reddy's Laboratories Ltd, Amneal Pharmaceuticals Inc., Hikma Pharmaceuticals plc, LEO Pharma A/S, Basilea Pharmaceutica Ltd., UCB S.A., Almirall SA, Lipella Pharmaceuticals Inc.
North America was the largest region in the lichen planus market in 2025. The regions covered in the lichen planus market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lichen planus market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the lichen planus market by increasing costs of imported topical formulations, systemic immunosuppressive drugs, biologics, and phototherapy equipment. Dermatology clinics and hospitals in North America and Europe are most affected due to reliance on imported specialty pharmaceuticals, while Asia-Pacific faces cost pressures on drug manufacturing inputs. These tariffs are increasing treatment costs and affecting therapy accessibility. However, they are also encouraging local drug formulation, regional manufacturing of dermatological treatments, and greater investment in domestic specialty pharmaceuticals.
The lichen planus market research report is one of a series of new reports that provides lichen planus market statistics, including lichen planus industry global market size, regional shares, competitors with a lichen planus market share, detailed lichen planus market segments, market trends and opportunities, and any further data you may need to thrive in the lichen planus industry. This lichen planus market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Lichen planus is a persistent inflammatory condition that targets the skin, mucous membranes, and occasionally the nails or hair. It is marked by the appearance of purplish, itchy, flat-topped lesions, typically seen on the wrists, ankles, and lower back. The condition can also impact the inside of the mouth, leading to white, lace-including patches or painful ulcers.
The primary forms of the disease include lichen planus, oral lichen planus, genital lichen planus, and lichen planus pigmentosus. It is a chronic autoimmune disorder in which the immune system erroneously attacks the skin and mucous membranes. Treatment options encompass topical therapies, systemic therapies, phototherapy, and alternative approaches. These therapies are administered through various routes, including topical, oral, intravenous, and intradermal methods, and are used across healthcare settings such as hospitals, homecare, specialty clinics, and other facilities.
The lichen planus market consists of revenues earned by entities by providing services such as narrowband UVB therapy, oral hygiene counseling, and dental check-ups. The market value includes the value of related goods sold by the service provider or included within the service offering. The lichen planus market also includes sales of topical corticosteroids, systemic immunosuppressants, antihistamines, biologic therapies, phototherapy equipment, diagnostic tools, and herbal and alternative remedies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The lichen planus market size is expected to see strong growth in the next few years. It will grow to $1.76 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to growing demand for advanced immunotherapies, rising focus on long-term symptom control, expansion of biologic treatment research, increasing integration of digital dermatology tools, advancements in targeted anti-inflammatory drugs. Major trends in the forecast period include increasing adoption of targeted immunomodulatory therapies, rising use of topical and systemic treatment combinations, increasing focus on chronic disease management, expansion of personalized dermatology care, improved patient education and disease monitoring.
The rising prevalence of autoimmune diseases is expected to drive the growth of the lichen planus market in the coming years. Autoimmune diseases are conditions in which the immune system mistakenly attacks the body’s own healthy cells and include disorders such as rheumatoid arthritis, lupus, type 1 diabetes, multiple sclerosis, and psoriasis. The increasing occurrence of autoimmune diseases is largely attributed to genetic predisposition, as certain gene variations influence immune system behavior and connective tissue abnormalities. This growing burden of autoimmune conditions reflects broader immune system dysregulation and contributes to a higher incidence of lichen planus. For example, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, approximately 514,000 people, or 2% of the population, were living with rheumatoid arthritis in 2022. This condition accounted for 2% of the total disease burden and 16% of the musculoskeletal disease burden in 2023, with 1,322 deaths recorded in 2022, representing 0.7% of all deaths. Therefore, the increasing prevalence of autoimmune diseases is contributing to the expansion of the lichen planus market.
Major companies operating in the lichen planus market are focusing on the development of innovative treatment approaches, such as liposomal formulations, to improve targeted drug delivery and reduce systemic side effects. Liposomal formulations are advanced drug delivery systems in which active pharmaceutical ingredients are encapsulated within lipid-based vesicles, enhancing drug stability, absorption, and targeted delivery while minimizing unwanted systemic exposure. For instance, in February 2025, Lipella Pharmaceuticals Inc., a US-based biotechnology company specializing in treatments for serious diseases, received approval from the US Food and Drug Administration for an expanded access program for LP-310. This therapy is a liposomal formulation of tacrolimus designed to provide targeted symptom relief for patients with oral lichen planus while limiting systemic absorption. The expanded access program allows patients with serious or life-threatening conditions and unmet medical needs to access the treatment outside of clinical trials prior to formal regulatory approval.
In September 2024, Eli Lilly and Company, a US-based pharmaceutical firm, partnered with EVA Pharma to expand access to baricitinib (Olumiant) across 49 low- and middle-income countries in Africa. The collaboration aims to reach approximately 20,000 patients by 2030, addressing conditions including lichen planus, rheumatoid arthritis, alopecia areata, and atopic dermatitis. Under the agreement, Eli Lilly will share specific manufacturing expertise to enable EVA Pharma to locally manufacture and distribute the medication. EVA Pharma is an Egypt-based pharmaceutical company engaged in the production and commercialization of generic prescription medicines across multiple therapeutic areas.
Major companies operating in the lichen planus market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc, AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Dr. Reddy's Laboratories Ltd, Amneal Pharmaceuticals Inc., Hikma Pharmaceuticals plc, LEO Pharma A/S, Basilea Pharmaceutica Ltd., UCB S.A., Almirall SA, Lipella Pharmaceuticals Inc.
North America was the largest region in the lichen planus market in 2025. The regions covered in the lichen planus market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lichen planus market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the lichen planus market by increasing costs of imported topical formulations, systemic immunosuppressive drugs, biologics, and phototherapy equipment. Dermatology clinics and hospitals in North America and Europe are most affected due to reliance on imported specialty pharmaceuticals, while Asia-Pacific faces cost pressures on drug manufacturing inputs. These tariffs are increasing treatment costs and affecting therapy accessibility. However, they are also encouraging local drug formulation, regional manufacturing of dermatological treatments, and greater investment in domestic specialty pharmaceuticals.
The lichen planus market research report is one of a series of new reports that provides lichen planus market statistics, including lichen planus industry global market size, regional shares, competitors with a lichen planus market share, detailed lichen planus market segments, market trends and opportunities, and any further data you may need to thrive in the lichen planus industry. This lichen planus market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Lichen planus is a persistent inflammatory condition that targets the skin, mucous membranes, and occasionally the nails or hair. It is marked by the appearance of purplish, itchy, flat-topped lesions, typically seen on the wrists, ankles, and lower back. The condition can also impact the inside of the mouth, leading to white, lace-including patches or painful ulcers.
The primary forms of the disease include lichen planus, oral lichen planus, genital lichen planus, and lichen planus pigmentosus. It is a chronic autoimmune disorder in which the immune system erroneously attacks the skin and mucous membranes. Treatment options encompass topical therapies, systemic therapies, phototherapy, and alternative approaches. These therapies are administered through various routes, including topical, oral, intravenous, and intradermal methods, and are used across healthcare settings such as hospitals, homecare, specialty clinics, and other facilities.
The lichen planus market consists of revenues earned by entities by providing services such as narrowband UVB therapy, oral hygiene counseling, and dental check-ups. The market value includes the value of related goods sold by the service provider or included within the service offering. The lichen planus market also includes sales of topical corticosteroids, systemic immunosuppressants, antihistamines, biologic therapies, phototherapy equipment, diagnostic tools, and herbal and alternative remedies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Lichen Planus Market Characteristics
3. Lichen Planus Market Supply Chain Analysis
4. Global Lichen Planus Market Trends and Strategies
5. Lichen Planus Market Analysis of End Use Industries
7. Global Lichen Planus Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Lichen Planus Total Addressable Market (TAM) Analysis for the Market
9. Lichen Planus Market Segmentation
10. Lichen Planus Market Regional and Country Analysis
11. Asia-Pacific Lichen Planus Market
12. China Lichen Planus Market
13. India Lichen Planus Market
14. Japan Lichen Planus Market
15. Australia Lichen Planus Market
16. Indonesia Lichen Planus Market
17. South Korea Lichen Planus Market
18. Taiwan Lichen Planus Market
19. South East Asia Lichen Planus Market
20. Western Europe Lichen Planus Market
21. UK Lichen Planus Market
22. Germany Lichen Planus Market
23. France Lichen Planus Market
24. Italy Lichen Planus Market
25. Spain Lichen Planus Market
26. Eastern Europe Lichen Planus Market
27. Russia Lichen Planus Market
28. North America Lichen Planus Market
29. USA Lichen Planus Market
30. Canada Lichen Planus Market
31. South America Lichen Planus Market
32. Brazil Lichen Planus Market
33. Middle East Lichen Planus Market
34. Africa Lichen Planus Market
36. Lichen Planus Market Competitive Landscape and Company Profiles
37. Lichen Planus Market Other Major and Innovative Companies
40. Lichen Planus Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Lichen Planus Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses lichen planus market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for lichen planus? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The lichen planus market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Disease Type: Lichen Planus; Oral Lichen Planus; Genital Lichen Planus; Lichen Planus Pigmentosus2) By Treatment Type: Topical Therapies; Systemic Therapies; Phototherapy
3) By Route Of Administration: Topical; Oral; Intravenous
4) By End User: Hospitals; Homecare; Specialty Clinics; Other End-Users
Subsegments:
1) By Lichen Planus: Papular Lichen Planus; Hypertrophic Lichen Planus; Actinic Lichen Planus; Linear Lichen Planus; Annular Lichen Planus2) By Oral Lichen Planus: Reticular Oral Lichen Planus; Erosive Oral Lichen Planus; Atrophic Oral Lichen Planus; Plaque-Like Oral Lichen Planus; Bullous Oral Lichen Planus
3) By Genital Lichen Planus: Erosive Genital Lichen Planus; Papular Genital Lichen Planus; Annular Genital Lichen Planus; Vulvovaginal-Gingival Syndrome
4) By Lichen Planus Pigmentosus: Diffuse Lichen Planus Pigmentosus; Blotchy Lichen Planus Pigmentosus; Linear Lichen Planus Pigmentosus; Perifollicular Lichen Planus Pigmentosus; Flexural Lichen Planus Pigmentosus
Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc; AbbVie Inc.; Sanofi SA; Bristol-Myers Squibb Company; Novartis AG; GlaxoSmithKline plc; Takeda Pharmaceutical Company; Eli Lilly and Company; Teva Pharmaceutical Industries Ltd.; Boehringer Ingelheim International GmbH; Dr. Reddy's Laboratories Ltd; Amneal Pharmaceuticals Inc.; Hikma Pharmaceuticals plc; LEO Pharma A/S; Basilea Pharmaceutica Ltd.; UCB S.A.; Almirall SA; Lipella Pharmaceuticals Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Lichen Planus market report include:- Pfizer Inc.
- Johnson & Johnson Services Inc.
- F. Hoffmann-La Roche AG
- Merck & Co. Inc
- AbbVie Inc.
- Sanofi SA
- Bristol-Myers Squibb Company
- Novartis AG
- GlaxoSmithKline plc
- Takeda Pharmaceutical Company
- Eli Lilly and Company
- Teva Pharmaceutical Industries Ltd.
- Boehringer Ingelheim International GmbH
- Dr. Reddy's Laboratories Ltd
- Amneal Pharmaceuticals Inc.
- Hikma Pharmaceuticals plc
- LEO Pharma A/S
- Basilea Pharmaceutica Ltd.
- UCB S.A.
- Almirall SA
- Lipella Pharmaceuticals Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 1.35 Billion |
| Forecasted Market Value ( USD | $ 1.76 Billion |
| Compound Annual Growth Rate | 6.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
